Therapeutic Antibody Primer

Therapeutic Antibody Primer

Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this...
It’s A Great Time To Be In Biotech

It’s A Great Time To Be In Biotech

It’s a great time to be in biotech—new therapeutics are breaking ground faster than we can say “monoclonal antibody” and the technologies behind them are heavy with promise and potential. Our mission is to keep your industry knowledge up to date and the WEEKLY is here...

First-in-Class: 2014 Drug Approvals

The FDA ushered in six new drugs just before the close of 2014, bringing the final tally to 41– the highest rate since 1996, when the agency approved 53 drugs. 2014 drug approvals were notable not only for their quantity, but also their quality. A number of new drugs...

The Bispecific Antibody: A Lethal Hybrid

Amgen’s acute lymphoblastic leukemia treatment, Blincyto, coasted past the FDA bottleneck ahead of schedule, gaining approval earlier this month as a “first of its kind” immunotherapy. The FDA designated Blincyto as a breakthrough therapy and an orphan product on top...